Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients

Yao Chun Hsu*, Lein Ray Mo, Chi Yang Chang, Ming Shiang Wu, Jia Horng Kao, Wen Lun Wang, Tzeng Huey Yang, Chaur Shine Wang, Ming Feng Chiang, Chieh Chang Chen, Yu Jen Fang, Hsu Wei Hung, Chun Ying Wu, Jaw Town Lin

*此作品的通信作者

研究成果: Article同行評審

44 引文 斯高帕斯(Scopus)

摘要

Background & Aims This study investigated whether serum level of hepatitis B surface antigen (HBsAg) at the end of entecavir treatment was associated with risk of relapse. Methods We performed a prospective multicenter study of 161 consecutive patients with chronic hepatitis B in whom the hepatitis B virus was no longer detected after 3 years or more of entecavir therapy. Treatment ended between July 1, 2011 and July 1, 2015. Patients were monitored for clinical relapse (hepatitis B virus DNA >2000 IU/mL and level of alanine aminotransferase more than 2-fold the upper limit of normal) and virologic relapse (hepatitis B virus DNA >2000 IU/mL). Outcomes were calculated using the Kaplan-Meier method and risk factors were identified by Cox proportional hazards modeling. Results Two years after therapy ended, 49.2% of patients in the entire cohort had a clinical relapse (95% confidence interval [CI], 40.9%–58.1%) and 81.7% had a virologic relapse (95% CI, 74.3%–88.0%). Among patients who were hepatitis B e antigen–negative at the end of therapy, 39.2% had a clinical relapse (95% CI, 30.3%–49.6%) and 77.4% had a virologic relapse (95% CI, 68.6%–85.2%). Serum level of HBsAg was associated with relapse in the hepatitis B e antigen–negative patients (Ptrend = .006 for clinical relapse; Ptrend = .0001 for virologic relapse). In multivariate Cox regression analysis, the hazard ratio (per log IU/mL increment) for clinical relapse was 2.47 (95% CI, 1.45–4.23) and for virologic relapse was 1.80 (95% CI, 1.33–2.45). The 11 (9%) patients with levels of HBsAg <10 IU/mL did not relapse. Conclusions Serum level of HBsAg is associated with risk of relapse in patients who are hepatitis B e antigen–negative after treatment with entecavir. A low titer of HBsAg might be used to identify patients at low risk for relapse after treatment.

原文English
頁(從 - 到)1490-1498.e3
期刊Clinical Gastroenterology and Hepatology
14
發行號10
DOIs
出版狀態Published - 1 10月 2016

指紋

深入研究「Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients」主題。共同形成了獨特的指紋。

引用此